
Investing.com -- European Union competition regulators are set to order U.S. biotech group Illumina (NASDAQ:ILMN) to sell cancer test development unit Grail following an $8 billion purchase of the firm that was unauthorized by Brussels, according to the Financial Times.
Citing three people with knowledge of the matter, the FT reported the EU could issue the order as soon as next week, although this timing could still slip.
The paper quoted one source as saying that Illumina "bought something illegally and now they need to sell it."
Illumina and Brussels have been at odds since 2021, when the San Diego-based company finished its purchase of Grail even though EU authorities had not yet completed their investigation into the competition implications of the transaction.
The EU later moved to block the deal before evenutally fining Illumina €432 million in July. Illumina has argued that because Grail does not generate any revenues in Europe, the purchase cannot be subject to scrutiny by Brussels.
New York-listed Illumina plans to appeal any orders to sell Grail, unnamed sources told the FT.
Shares in Illumina were lower in early U.S. trading on Monday.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.